Literature DB >> 12625799

Managing treatment-resistant major depression.

J Craig Nelson1.   

Abstract

A sizable proportion of patients suffering from nonpsychotic unipolar depression experience only partial or no clinical response to antidepressant treatment. Switching, augmenting, and combining various pharmaceutical agents can be effective strategies for patients with treatment-resistant depression. The empirical evidence supporting these approaches is inconsistent, however, and there is a paucity of controlled studies to support their efficacy. Additionally, it has been difficult to demonstrate the advantages of these strategies over increasing the dose or duration of the initial drug treatment. This article will review available evidence and clinical considerations regarding switching, augmenting, and combining various agents in the treatment of patients suffering from nonpsychotic unipolar depression who have failed adequate courses of antidepressant treatment. More research is needed that controls for continued time on the initial agent, that compares different strategies, and that determines which patients are the best candidates for which treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12625799

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.

Authors:  Matthew A Seager; Vanessa N Barth; Lee A Phebus; Kurt Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 2.  Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature.

Authors:  James K Rustad; Theodore A Stern; Kathy A Hebert; Dominique L Musselman
Journal:  Prim Care Companion CNS Disord       Date:  2013-08-15

3.  Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Authors:  Antonio Tundo; Rocco de Filippis; Luca Proietti
Journal:  World J Psychiatry       Date:  2015-09-22

4.  A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.

Authors:  Gabor I Keitner; Steven J Garlow; Christine E Ryan; Philip T Ninan; David A Solomon; Charles B Nemeroff; Martin B Keller
Journal:  J Psychiatr Res       Date:  2008-06-30       Impact factor: 4.791

5.  Contemporary concepts in the pharmacotherapy of depression in older people.

Authors:  Carlos Rojas-Fernandez; Mina Mikhail
Journal:  Can Pharm J (Ott)       Date:  2012-05

6.  Gene expression biomarkers of response to citalopram treatment in major depressive disorder.

Authors:  F Mamdani; M T Berlim; M-M Beaulieu; A Labbe; C Merette; G Turecki
Journal:  Transl Psychiatry       Date:  2011-06-21       Impact factor: 6.222

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates.

Authors:  M Guo; X-Y Lu
Journal:  Transl Psychiatry       Date:  2014-12-02       Impact factor: 6.222

9.  Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.

Authors:  Sarah Sharman Moser; Gabriel Chodick; Shulamit Gelerstein; Nava Barit Ben David; Varda Shalev; Orit Stein-Reisner
Journal:  BMC Psychiatry       Date:  2022-08-11       Impact factor: 4.144

10.  The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial.

Authors:  Yves Chaput; Annick Magnan; Alain Gendron
Journal:  BMC Psychiatry       Date:  2008-08-28       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.